A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

Exclusion Criteria

• •1. Participants with a secondary cause of MN
• •2. Cyclosporine resistance
• •3. Urine protein decreased by \> 50% within 6 months before screening
• •4. Received treatment drugs for membranous nephropathy
• •5. Concomitant with other serious diseases
• •6. Received live vaccination, major surgery (excluding diagnostic procedures), and participated in other clinical trials within 28 days prior to receiving the first study drug
• •7. Patients who are positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), with HBV DNA levels above the normal range (HBsAg and/or HBcAb-positive patients require regular HBV DNA testing); patients positive for hepatitis C virus (HCV) antibodies; or patients with a positive human immunodeficiency virus (HIV) serology
• •8. Participants with CD4+ T lymphocyte count \< 300 cells/μL
• •9. Those who have a clear history of tuberculosis or have received anti- tuberculosis treatment
• •10. Participants with known history of severe allergic reactions to humanized monoclonal antibodies, MIL62, or Cyclosporine
• •11. Breastfeeding or pregnant women
• •12. Childbearing potential and unwillingness or impossibility to comply with a scientifically acceptable birth-control method
• •13. Other conditions unsuitable for participation in this study determined by the Investigator